Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study.

Takaya Ikeda Shinnosuke TakemotoHiroaki SenjuHiroshi GyotokuHirokazu TaniguchiMidori ShimadaYosuke DotsuYasuhiro UmeyamaHiromi TomonoTakeshi KitazakiMasaaki FukudaHiroshi SodaHiroyuki YamaguchiMinoru FukudaHiroshi Mukae

Published in: Thoracic cancer (2020)

There was not enough data to evaluate the efficacy because the study was terminated early. However, amrubicin showed limited activity and acceptable toxicities when used in previously treated malignant pleural mesothelioma patients.

Keyphrases

phase ii study
newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
open label
locally advanced
randomized controlled trial
squamous cell carcinoma
electronic health record
rectal cancer